27th week of 2011 patent applcation highlights part 31 |
Patent application number | Title | Published |
20110165126 | Enhanced Submucosal Tissue Graft Constructs - An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo. | 2011-07-07 |
20110165127 | DAIRY-DERIVED PROBIOTIC COMPOSITIONS AND USES THEREOF - The present application relates to a dairy-derived probiotic composition comprising a propionic bacteria. The composition is particularly useful as a food supplement for normalizing the gastro-intestinal flora. The probiotic bacteria present in the composition contain species of | 2011-07-07 |
20110165128 | HOMING IN MESENCHYMAL STEM CELLS - The present invention relates to expression of CXCR4 in mesenchymal stem cells (MSCs) and homing of MSCs to sites of injury. In particular, the invention provides expanded cultures of MSCs which maintain cell surface expression of CXCR4. The MSCs are capable of homing to sites of injury and are suitable for treatment of ischemic disorders, including cardiac disorders, bone and cartilage disorders, liver disorders, inflammatory disorders, and stroke. | 2011-07-07 |
20110165129 | Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition. | 2011-07-07 |
20110165130 | Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells - The present invention relates to an ex vivo method for obtaining a population of human keratinocytes derived from human pluripotent stem cells comprising a step of co-culturing human pluripotent stem cells with cells that support ectodermal differentiation in presence of an agent that stimulates epidermal induction and a agent that stimulates terminal differentiation of keratinocytes. A further object of the invention relates to a method for preparing a human skin substitute comprising a step of providing an organotypic culture of the substantially pure homogenous population of human keratinocytes derived from human pluripotent stem cells obtained according to the method of the invention. | 2011-07-07 |
20110165131 | METHODS FOR TREATING DISEASES AND INCREASING LONGEVITY - Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans. | 2011-07-07 |
20110165132 | Heparan Sulphate Which Binds BMP2 - The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS). | 2011-07-07 |
20110165133 | METHOD OF DE-DIFFERENTIATING AND RE-DIFFERENTIATING SOMATIC CELLS USING RNA - RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system. | 2011-07-07 |
20110165134 | LACTOBACILLUS SP. JNU2116 WITH ANTIMUTAGENIC ACTIVITY - sp. strain with antimutagenic activity and, more particularly, | 2011-07-07 |
20110165135 | LACTOBACILLUS HELVETICUS STRAINS FOR PRODUCING HYPOTENSIVE PEPTIDES - The present invention relates to novel strains of | 2011-07-07 |
20110165136 | Novel Herbal Composition for Treatment of Psoriasis and Other Skin Disorders - The invention relates to a herbal composition for the treatment of psoriasis and other skin disorders. The herbal composition comprises the extracts of | 2011-07-07 |
20110165137 | SUPPRESSION OF CANCERS - The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods. | 2011-07-07 |
20110165138 | PROTOCOLS FOR TREATING AND PREVENTING OBESITY AND COMPLICATIONS ARISING THEREFROM - The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes. | 2011-07-07 |
20110165139 | GROWTH HORMONE SECRETION STIMULATOR - Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by using a milk-derived basic protein fraction. The agent for promoting growth hormone-secretion may be ingested on a daily basis and is highly safe even with its ingestion for a long period. | 2011-07-07 |
20110165140 | Dry Transglutaminase Composition - The present invention relates to a dry transglutaminase composition, said composition is obtainable by lyophilizing or spray-drying an aqueous composition comprising a transglutaminase, a salt and at least one further component selected from the group consisting of a sugar, an amino acid, and a buffer, wherein the concentration of the salt in the aqueous composition is in the range from 5 to 100 mM. In further aspects, the present invention relates to a method of preparing said dry transglutaminase composition, a reconstituted solution, a pharmaceutical composition, and method of treatments. | 2011-07-07 |
20110165141 | Compositions for treating bacterial infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 2011-07-07 |
20110165142 | METHOD OF TREATING DEGENERATIVE DISEASES - Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy. | 2011-07-07 |
20110165143 | MODULATION OF CASPASES AND THERAPEUTICAL APPLICATIONS - The present invention provides caspase modulators in a wide variety of therapeutic applications. Some aspects of the present invention provide methods for using caspase modulators in treating tumor, promoting wound healing, and producing induced pluripotent stem cells. | 2011-07-07 |
20110165144 | METHODS FOR TREATING RHEUMATOID ARTHRITIS - Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling. | 2011-07-07 |
20110165145 | IGF-II/IGF-IIE BINDING PROTEINS - Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor. | 2011-07-07 |
20110165146 | METHODS OF DIAGNOSING ALZHEIMER'S DISEASE - Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease. | 2011-07-07 |
20110165147 | NOVEL 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 AND 26908 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2011-07-07 |
20110165148 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 162P1E6 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization. | 2011-07-07 |
20110165149 | TARGETING ABCB5 FOR CANCER THERAPY - The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 2011-07-07 |
20110165150 | Isolated organ perfusion combination therapy of cancer - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone. | 2011-07-07 |
20110165151 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 2011-07-07 |
20110165152 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 2011-07-07 |
20110165153 | ANTI CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology. | 2011-07-07 |
20110165154 | COMPOSITIONS AND METHODS USING ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA - Compositions and methods for treating MM are provided herein. | 2011-07-07 |
20110165155 | METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 - Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. | 2011-07-07 |
20110165156 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2011-07-07 |
20110165157 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 2011-07-07 |
20110165158 | METHODS FOR THE THERAPY OF INFLAMMATORY BOWEL DISEASE USING A TYPE-1 INTERFERON ANTAGONIST - Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR). | 2011-07-07 |
20110165159 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 2011-07-07 |
20110165160 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 2011-07-07 |
20110165161 | ANTI-EPCAM ANTIBODIES THAT INDUCE APOPTOSIS OF CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to epithelial cell adhesion/activating molecule EpCAM expressed on cancer cells and induce cancer cell apoptosis. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes. | 2011-07-07 |
20110165162 | Methods for Treating Cancers Comprising K-ras Mutations - Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a K-ras mutation. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 2011-07-07 |
20110165163 | IDENTIFICATION OF A CONSERVED INNER CORE OLIGOSACCHARIDE OF MORAXELLA CATARRHALIS LIPOPOLYSACCHARIDE AS A VACCINE ANTIGEN - There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium | 2011-07-07 |
20110165164 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS - Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described. | 2011-07-07 |
20110165165 | MAMMALIAN GENES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 2011-07-07 |
20110165166 | LSR RECEPTOR, ITS ACTIVITY, ITS CLONING, AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS - The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines. | 2011-07-07 |
20110165167 | NOVAL MADCAM ANTIBODIES - The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease. | 2011-07-07 |
20110165168 | CIDEA MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-07-07 |
20110165169 | COMPLEMENT INHIBITORS AND USES THEREOF - The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2011-07-07 |
20110165170 | OSTEOPONTIN ANTIBODIES - The present disclosure provides isolated antibodies, particularly human antibodies, or antigen binding portions thereof, that bind to osteopontin with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. | 2011-07-07 |
20110165171 | ANTIBODIES THAT BIND PAR-2 - The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions. | 2011-07-07 |
20110165172 | METHOD OF TREATING A STAPHYLOCOCCUS INFECTION IN A PATIENT HAVING A LOW-LEVEL PATHOGENIC PSEUDOMONAS AERUGINOSA INFECTION - This invention provides methods of treating patients having a | 2011-07-07 |
20110165173 | THERAPEUTIC AGENT AND DETECTION REAGENT FOR ARTERIOSCLEROTIC DISEASE WHICH TARGETS FOR SALUSIN - The present invention provides a prophylactic and therapeutic agent for arteriosclerotic diseases and a method or reagent for detecting arteriosclerotic diseases. Further, the present invention provides a therapeutic agent for an arteriosclerotic disease, comprising salusin-α as an active ingredient, a therapeutic agent for an arteriosclerotic disease, comprising an antagonist of salusin-β as an active ingredient, and a method for detecting an arteriosclerotic disease, comprising assaying salusin-α in a biological sample. | 2011-07-07 |
20110165174 | Alternatively Transcribed Genes Associated with Memory Consolidation - Methods of identifying gene targets associated with learning and memory and with memory consolidation, as well as to specific nucleic acid molecules that have been discovered to be associated with memory consolidation are provided. Accordingly, the invention also relates to methods of modulating learning and memory function, methods of diagnosing learning and memory disorders, and methods of identifying compounds that modulate learning and memory function via manipulations of the nucleic acid molecules and their products. | 2011-07-07 |
20110165175 | ANTIBODY OF HUMAN ORIGIN FOR INHIBITING THROMBOCYTES AGGREGATION - The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa. | 2011-07-07 |
20110165176 | ALDOSTERONE INDUCED VASCULAR ELASTIN PRODUCTION - Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein. | 2011-07-07 |
20110165177 | Methods of Modulating Immunity - The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration. | 2011-07-07 |
20110165178 | DIAGNOSIS OF PROSTATE CANCER - The present invention relates to vitro diagnosis methods of prostate cancer from a test biological sample, comprising measuring the expression level of KIAA0153 in said test biological sample, as well as to methods for screening compounds inhibiting KIAA0153 gene expression or biological activity and uses of such KIAA0153 inhibiting compounds. | 2011-07-07 |
20110165179 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 2011-07-07 |
20110165180 | Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses - The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment. | 2011-07-07 |
20110165181 | RELAY VACCINE - The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM | 2011-07-07 |
20110165182 | CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE - The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate. | 2011-07-07 |
20110165183 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS - The invention provides a compound of formula (I): wherein W is a bicyclic heteroaromatic group; or a salt thereof. The compounds and salts thereof have beneficial therapeutic properties (e.g. immunosuppressant properties). | 2011-07-07 |
20110165184 | CDH3 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME - The present invention provides a peptide of the following (A) or (B):
| 2011-07-07 |
20110165185 | IMMUNOGENIC PEPTIDES - The invention provides relatively short immunogenic peptides derived from CD19 and CD20 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer. | 2011-07-07 |
20110165186 | NOVEL PYRIDINE ALKALOIDS, PREPARATION PROCESS THEREOF, AND THE USES OF THE PYRIDINE ALKALOIDS - The present invention relates to novel pyridine alkaloid compounds of formula (I): | 2011-07-07 |
20110165187 | TUMOR CELLS FROM IMMUNE PRIVILEGED SITES AS BASE CELLS FOR CELL-BASED CANCER VACCINES - The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells. | 2011-07-07 |
20110165188 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE - The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof. | 2011-07-07 |
20110165189 | RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE - Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein. | 2011-07-07 |
20110165190 | Compositions and Methods for Immunizing Against Immunodeficiency Viruses - Disclosed are compositions, kits, and methods related to HIV vaccines and immunogenic compositions. Typically, the compositions include a mixture of individual and separate DNA polynucleotides that encode different HIV polypeptides or fragments thereof. The mixture of polynucleotides is designed to elicit a broad immunogenic response which may be subsequently boosted by administering a second composition such as a recombinant virus vector composition. The compositions, kits, and methods may be utilized for treating or preventing HIV infection or disease. | 2011-07-07 |
20110165191 | TAT DNA SEQUENCES, GENE CONSTRUCTS, VACCINE AND PROCESSES THEREOF - The present invention relates to non toxic, immunogenic viral Tat DNA sequences comprising wherein the Tat Sequence is rendered non toxic and immunogenic by insertion of T-Helper Epitope into the Cysteine-rich domain, or Basic domain or Core domain of said Tat DNA sequence, optionally along with insertion of a synthetic Intron between C-terminal region and Exon II region of the Tat DNA Sequence. The present invention also relates to elongation factor promoter constructs and process thereof. Also the present invention relates to a process of obtaining the non toxic and immunogenic Tat DNA sequence and vaccine and a method thereof. | 2011-07-07 |
20110165192 | Methods for producing vaccine adjuvants - An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. | 2011-07-07 |
20110165193 | Methods for producing vaccine adjuvants - An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. | 2011-07-07 |
20110165194 | HBV Vaccine and a Process of Preparing the Same - The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response. | 2011-07-07 |
20110165195 | COMPOSITION FOR MUCOSAL ADMINISTRATION CONTAINING AGENT FOR ENHANCING MUCOSAL ABSORPTION OF PEPTIDE DRUG, AND ADMINISTRATION METHOD THEREOF - A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium | 2011-07-07 |
20110165196 | Method for treatment of crib biting in animals - The present invention generally relates to methods for treating cribbing behavior in animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the sternocephalic muscle, thereby denervating these muscles and preventing cribbing behavior. | 2011-07-07 |
20110165197 | ADJUVANT COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES - The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE. | 2011-07-07 |
20110165198 | METHOD FOR REDUCING LIPID ABSORPTION BY AN ANIMAL - The invention provides methods for using fatty acid alkanolamides for reducing lipid absorption from the intestine of an animal. Reducing lipid absorption results in fewer lipids available for an animal to convert to body fat. Converting fewer lipids to body fat means that the animal reduces body fat, body weight, and/or body weight gain when consuming an equivalent amount of lipids without the fatty acid alkanolamides. | 2011-07-07 |
20110165199 | Composition and Process for Bone Growth and Repair - A composition for the induction of bone growth is disclosed. The composition includes a substrate, bone growth protein, and sources of calcium and phosphate. The composition is acidic which promotes high activity of the bone growth protein. The calcium and phosphate sources can be provided as an acidic calcium phosphate salt. Also disclosed are methods of the making the composition and methods of using it. | 2011-07-07 |
20110165200 | NOVEL HYDROGELS AND USES THEREOF - The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the solution that may be changed include pH, ionic strength, temperature, and concentration of one or more specific ions. In addition, hydrogels of the invention may be disassembled by changing one or more characteristic of the hydrogel such as pH, ionic strength, temperature, and concentration of one or more specific ions. | 2011-07-07 |
20110165201 | ANTICANCER FORMULATION - This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor. | 2011-07-07 |
20110165202 | SOLID STATE FORMS OF FOSAMPRENAVIR CALCIUM SALT AND PROCESSES FOR PREPARATION THEREOF - The present invention relates to solid state forms of fosamprenavir calcium salt, process for preparing said solid state forms, and pharmaceutical compositions thereof. | 2011-07-07 |
20110165203 | A TOPICAL COMPOSITION COMPRISING THE ISOLATED NON-POLAR LIPID FRACTION OF LANOLIN4 - A topical composition comprising the isolated non-polar lipid fraction of lanolin, and one or more additional compounds selected from ceramides, cholesterol and free fatty acids. | 2011-07-07 |
20110165204 | GASTRIC THERAPIES AND COMPOSITIONS THEREFOR - The invention relates to compositions and methods for the treatment of gastric and/or duodenal | 2011-07-07 |
20110165205 | NANOVECTOR WITH POSITIVE CHARGE SUBSTANTIVE FOR HAIR AND SKIN - “NANOVECTOR WITH POSITIVE CHARGE SUBSTANTIVE FOR HAIR AND SKIN”, to be applied directly on the skin or hair, or to be added to the preparation of a cosmetic or dermopharmaceutical compositions in order to enhance the properties of said products; comprising empty particles dispersed in a water-based medium of the range of the nanometers; those particles have mainly the following components: a phospholipids membrane of any order and composition, and one or more quaternary polymers that provide it with a superficial positive charge, both components may be found in any concentration combination. | 2011-07-07 |
20110165206 | Preparation of Silicone Microemulsions - A mechanical method of making an oil-in-watermicroemulsion containing (A) a polysiloxane and (B) an inert fluid selected from an inert siloxane fluid and an inert organic fluid, where the average emulsion particle size is between 1 and 140 nanometers, is disclosed. The process involves the following steps: i) preparing an oil phase comprising a polysiloxane containing mixture by the polymerisation of silane or siloxane containing monomers and/or oligomers in the presence of an inert fluid, a suitable catalyst and optionally an end-blocking agent; and ii) where required quenching the polymerisation process; wherein the inert fluid is substantially retained within the resulting polysiloxane containing mixture; iii) if required, mixing one or more surfactants into the oil phase; iv) adding water to the oil phase, followed by applying agitation or shear to the mixture to arrive at an oil-in-water microemulsion; v) optionally diluting the oil-in-water microemulsion by adding more water. | 2011-07-07 |
20110165207 | PARTICULATE WAX COMPOSITES AND METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF - The invention relates to inorganic-organic composite particles, in particular composite nanoparticles, wherein the composite particles comprise at least one organically based material containing or being made of at least one wax and an inorganically based material, and to a method for the production thereof and to the use thereof | 2011-07-07 |
20110165208 | COLOR CAPSULE COMPOSITION FOR COSMETICS, PREPARATION METHOD THEREOF AND COSMETIC FORMULATION COMPRISING THE SAME - Disclosed herein are a color capsule composition, which contains a polymer and a plasticizer swelling the polymer so as to allow the capsule particles to easily break and in which the capsule particles have a porous structure that boosts the effects thereof, and a method for preparing the color capsule composition. The preparation method comprises: uniformly mixing a color pigment, a plasticizer and a polymer in a first solvent to produce a first mixture solution; spray-drying the first mixture solution to produce core particles in which the color pigment is covered by the polymer; uniformly mixing the obtained core particles, a functional pigment and a second solvent to produce a second mixture solution; and spray-drying the second mixture solution to produce in which a coating layer of the functional pigment is formed on the outer surface of the polymer. | 2011-07-07 |
20110165209 | Methodology and Composition for a Skin Lubricant - One possible embodiment of the invention could be a method of lubricating the human skin comprising of the following steps, providing a composition of a gel formed from cross-linking siloxane polyethers, the gel being further micronized in one or more low viscosity, silicone fluids; applying an effective amount of the composition to a portion of skin; reducing the frictional qualities of the portion of skin; applying a polymer garment that covers the portion of the skin; creating a plug of the composition in a pore of the portion of skin when a polymer garment covering that portion of the skin produces a partial pressure effect relative to that portion of skin; and reducing the amount of sweat that is produced by the pore. | 2011-07-07 |
20110165210 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2011-07-07 |
20110165211 | CARBON DIOXIDE EXTERNAL PREPARATION, AND MATERIAL FOR FORMATION OF CARBON DIOXIDE EXTERNAL PREPARATION - A material for formation of carbon dioxide external preparation of the present invention comprises a base agent and a reactant. The base agent comprises a polymeric three-dimensional network structure impregnated with a viscous material containing at least an acid and water, and is made to contact with the skin in use. The reactant contains at least a carbonate, and contacts with the aforementioned viscous material in use so as to generate carbon dioxide, the carbon dioxide dissolving in the viscous material substantially in a non-bubble state. | 2011-07-07 |
20110165212 | Nano antimicrobial personal protection gear - An antimicrobial protection gear for use by a person, the an antimicrobial protection gear comprising a 1 | 2011-07-07 |
20110165213 | Insecticidal Polymer Matrix Comprising HDPE and LDPE - An insecticidal polymer matrix containing HDPE (high density polyethylene), LDPE (low density polyethylene), preferably containing PBO (Piperonyl Butoxide) and DM (Deltamethrin), wherein the ratio of the contents of HDPE to LDPE is between 5 and 20 and most preferably between 8 and 10. The matrix is highly useful for bed nets against mosquitoes. | 2011-07-07 |
20110165214 | Use of a plastic composition and a product obtained thereby - Disclosed is a method of inactivating or destroying viruses on a product or article surface coming into contact with a mammal, including man, said method comprising providing said surface with a viricidal activity obtained by incorporating into said product or article, or by coating said product or article with an effective amount of at least one viricide or a composition comprising at least one viricide, wherein said viricide comprises (i) elemental silver deposited on glass particles having a particle size of 5-50 μm, said elemental silver being deposited in an amount of 0.5-5% by weight calculated on said glass particles, or (ii) a silver salt deposited on metal oxide particles having a particle size of 0.1-2 μm, said silver salt being deposited in a weight ratio silver salt to metal oxide of between 10:90 and 70:30, and wherein said viricide is present in an amount corresponding to between 0.001 and 1 g elemental silver/kg of said product or article. | 2011-07-07 |
20110165215 | COHESIVE OSTEOGENIC PUTTY AND MATERIALS THEREFOR - Described is an implantable medical material comprising a malleable, cohesive, shape-retaining putty including mineral particles, insoluble collagen fibers and soluble collagen. The medical material can be used in conjunction with biologically active factors such as osteogenic proteins to treat bone or other tissue defects in patients. | 2011-07-07 |
20110165216 | Hydrogen Sulfide Generating Polymers - Described herein are hydrogen sulfide (H | 2011-07-07 |
20110165217 | SCAFFOLDS WITH TRACE ELEMENT FOR TISSUE REGENERATION IN MAMMALS - A scaffold for implantation into a mammal to facilitate vessel growth in repair, regeneration, and/or proliferation of bodily tissue, where the scaffold is based on a borate, silicate, or phosphate, glass-former and is biodegradable upon implantation in mammals. The scaffold includes one or more trace elements from the group consisting of Cu, F, Fe, Mn, Mo, Ni, Sr, and Zn which are released into the host to support vessel growth. A method involves implantation of such scaffolds. | 2011-07-07 |
20110165218 | Therapeutic Bone Growth and Regeneration - The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia. | 2011-07-07 |
20110165219 | OPTIMIZATION OF ALGINATE ENCAPSULATION OF ISLETS FOR TRANSPLANTATION - Apparatus is provided, including a plurality of islets, and a hydrogel configured to macroencapsulate the plurality of islets. The hydrogel is implantable in a subcapsular space ( | 2011-07-07 |
20110165220 | DRUGS TO PREVENT HPV INFECTION - A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell. | 2011-07-07 |
20110165221 | WOUND CARE - A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P | 2011-07-07 |
20110165222 | TRANSDERMAL COMPOSITIONS CONTAINING LOW MOLECULAR WEIGHT DRUGS WHICH ARE LIQUID AT ROOM TEMPERATURES - A transdermal composition is disclosed which contains a blend of one or more polymers, one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures. The composition is substantially free of water and liquids which have a normal boiling point (a) optionally below processing temperatures and (b) greater than or equal to the temperature of the low molecular weight drugs. The composition does not suffer from the substantial loss of the lower molecular weight drug during production of the transdermal system. A transdermal composition is also disclosed which has one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures, and a polymer matrix including one or more high shear resistant polymers. The high shear resistant polymer(s) reduce the plasticizing effect of the low molecular weight drug, and has sufficient tack and shear for application to a human being. | 2011-07-07 |
20110165223 | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen - The present invention relates to methods for preventing, reducing or treating a variety of conditions, including cancer, and vaccines, compositions and liposomes used to elicit or amplify an immune response specific to the condition by delivering to the spleen of an individual a pegylated liposome construct having a diameter of greater than about 300 nm and including a therapeutic agent and an adjuvant for eliciting or amplifying the immune response. | 2011-07-07 |
20110165224 | VACCINES FOR INCLUSION BODY HEPATITIS - A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny. | 2011-07-07 |
20110165225 | Modified Drugs for Use in Liposomal Nanoparticles - Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags. | 2011-07-07 |